METHODS:
l Systematic review of submission processes for MN (including FSMP (European terminology of this food category) and Medical Food (US terminology)), combined with experience of the authors from previous research on health economics, Market Access and reimbursement.
l A systematic literature search was being conducted analysing the reimbursement pathways and requirements reported for France, Germany, UK and the US.
l Additionally relevant institutional sites were screened for relevant documents (e.g. G-BA, HAS, etc.)
l Search terms for MN (definition above): -Reimbursement, Market Access, Funding -Health Economics, Health Policy -France, Germany, UK, USA
RESULTS:
l Pathways for market access are provided in the table below.
SUMMARY:
l When considering MN delivered in the ambulatory care setting, only in France, innovative MN presenting with therapeutic value faces the medical device reimbursement process.
l In the UK, the process is handled by the ACBS and focus mainly on clinical outcome and safety; additionally this process sets a reimbursed price and allows innovation.
l In the US and Germany, there are reimbursed categories for MN linked to composition of the product and dedicated to patients with inability to have their nutritional needs covered by normal food intake (set by CMS in the US and G-BA in Germany).
l Creating new reimbursed categories linked to new MN either bringing innovative therapeutic value or targeting new disease area is highly difficult in all countries.
l For MN delivered in hospital settings, products delivered enterally or orally are mainly covered by hospital budget.
l The budget can be either from the hospital's kitchen for thickened and thickening products, under the diagnosis-related group funding scheme related to each countries, by the nutritionist budget (mainly UK and US) or by the hospital's pharmacy budget for specialties.
l For standard products, access is obtained based on tenders. In long-term care and nursing home, coverage and funding are more heterogeneous: they vary from highly regulated reimbursed scheme based on composition of the products and disease area to per diem fee per patient covering both food and MN.
CONCLUSIONS:
l The market access pathways for granting reimbursement or coverage of the medical nutrition category are very heterogeneous between the analyzed countries. Covered under the German DRG system for EN and feeding tubes; Non-standard products should be listed on hospital drugs list; Tender processes for generic products; or individual contract for innovative products.
Country

United-Kingdom
A notification letter should be sent to the FSA; Thereafter a dossier should be sent to the MHRA in order to obtain an exemption from drugs' regulation.
For generic products or products comparable to the competitors' one, a me-too dossier with rational, composition of the product should be submitted to the ACBS. For any changes in products' composition, a dossier should also be submitted with rational for this change and the new composition.
All products should fit within one of the 5 categories listed in the ACBS application guidance, categories which cover most of diseases. The ACBS decides on reimbursement agreement and reimbursed price.
A HTA dossier should be submitted with composition of the product, rational for it, disease targeted, safety and clinical data; medico-economics data can be submitted as well. All products should fit within the 5 categories listed in the ACBS application guidance for requesting coverage by the NHS of nutritional products. The ACBS decides on reimbursement agreement and reimbursed price. The reimbursement is granted for 5 years.
Covered by the British DRG system (HRG) or by dieticians' budget. Tender process exists for generic products. For innovative products, the rational for it with clinical data should be brought to physicians and dieticians.
USA
For most medical food products: free access to market; however products should be compliant with existing rules in case of post-launch control. For infant products, FDA requires trials to be done before launch.
Covered by Medicare in homecare setting for tube feeding if deemed medically necessary and if fitting with products coded into the HCPCS code. For getting a HCPCS code a dossier including rational and composition of the product should be submitted. Medicaid cover standard nutritional products only in specific programs. Private health plans barely cover medical food in outpatient care.
There is little opportunity for innovation, as the medical food HCPCS categories' list should be modified accordingly. 
